Spontaneous reduction of prolactinoma post cabergoline withdrawal
Prolactinomas are common pituitary tumors usually highly responsive to dopamine agonists. Around 70-90% of the prolactinomas exhibit decrease in tumor size, though variably with these agents. Uncommonly, there may be little or no shrinkage in pituitary tumor. In the absence of medical therapy, pitui...
Main Authors: | Sampath Kumar Venkatesh, Deepak Kothari, Smita Manchanda, Anil Taneja, Bindu Kulshreshtha |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2012;volume=16;issue=5;spage=833;epage=835;aulast=Venkatesh |
Similar Items
-
Second attempt of Cabergoline withdrawal in patients with prolactinomas after a failed first attempt : is it worthwhile?
by: Lucio eVilar, et al.
Published: (2015-02-01) -
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
by: Shruti Khare, et al.
Published: (2017-01-01) -
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
by: Annabelle G Hayes, et al.
Published: (2023-01-01) -
The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
by: Larisa Dzeranova, et al.
Published: (2016-11-01) -
Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
by: Bassam M Flamerz Arkawazi
Published: (2020-01-01)